HPLC-MS/MS-based Cytochrome P450 2C9 (CYP2C9) Inhibition Assessment Service
Creative Biolabs has launched the HPLC-MS/MS-based CYP2C9 inhibition assessment service, which provides accurate and reliable analysis for predicting potential drug-drug interactions and assessing the inhibition of CYP2C9, a key enzyme involved in drug metabolism. Our experienced team of experts provides high-quality data and science-based insights to help our clients make informed decisions about drug development and safety evaluation.
HPLC-MS/MS-based CYP Inhibition Assessment Platform
HPLC-MS/MS-based Cytochrome P450 2C9 (CYP2C9) Inhibition Assessment Service
CYP2C9
CYP2C9 is a gene that provides instructions for making an enzyme that is primarily found in the liver. This enzyme plays a role in metabolizing (breaking down) various drugs and other substances in the body. Variations in the CYP2C9 gene can affect how quickly or slowly the enzyme metabolizes certain drugs, leading to differences in drug effectiveness and potential side effects. Individuals with certain genetic variations in the CYP2C9 gene may require lower or higher doses of specific medications for optimal treatment outcomes.
What We Do
Assay design and development: Design and development of an optimized assay protocol for assessing CYP2C9 inhibition using HPLC-MS/MS.
Screening of test compounds: Testing of potential drug candidates or compounds for their ability to inhibit CYP2C9 activity.
IC50 determination: Determination of the half-maximal inhibitory concentration (IC50) of test compounds to quantify their inhibitory effect on CYP2C9.
Data analysis and interpretation: Analysis of the results obtained from the assay, including IC50 values, and interpretation of the potential implications for drug metabolism and drug-drug interactions.
Detailed Information of Our Service
|
Protein Name
|
Family
|
Sub Family
|
Uniprot Number
|
Gene Name
|
|
CYP2C9
|
CYP450
|
CYP2
|
P11712
|
CYP2C9
|
|
Gene ID
|
Gene Aliases
|
Organism
|
Construct Details
|
|
|
1559
|
P450IIC9
|
Human
|
Full-length, Recombi
|
|
Measured Response
Peak Area Response
Service Sub Type
Enzymatic
Detection Method
HPLC-MS/MS
Key Features of HPLC-MS/MS-based CYP2C9 Inhibition Assessment
-
Highly sensitive and specific HPLC-MS/MS method for quantifying CYP2C9 activity
-
Customized assay conditions tailored to the specific requirements of your ADME study
-
Comprehensive data analysis and interpretation by our team of expert scientists
-
Rapid turnaround times to meet your project timelines
Cooperation With Creative Biolabs
Frequently Asked Question
A1: When is an HPLC-MS/MS-based cytochrome CYP2C9 inhibition assessment assay required?
Q1: An HPLC-MS/MS-based cytochrome CYP2C9 inhibition assessment assay is typically required when evaluating the potential of a drug candidate or a chemical compound to inhibit CYP2C9 enzyme activity. This assay is essential for assessing the potential for drug-drug interactions, as CYP2C9 is an important enzyme in drug metabolism. It is also useful in predicting the likelihood of adverse drug reactions and determining the proper dose adjustments for drugs that are metabolized by CYP2C9.
Contact Us
To learn more about our HPLC-MS/MS-based CYP2C9 Inhibition Assessment Service and how it can benefit your drug development projects, please contact us now or you can click here to learn more about Cytochrome P450. Our dedicated ADME R&D team will be happy to discuss your specific needs with you and provide a customized solution to meet your CYP inhibition research objectives. Creative Biolabs also offers the following services, if you are interested, you can click directly to get the information!
In Vitro ADME Screening
High-Throughput ADME
Analysis of Drug Metabolic Stability
For Research Use Only | Not For Clinical Use
Download our brochure